Generalized anxiety disorder (GAD)--excessive or pathologic worry for at least 6 months--is a common psychiatric problem that is stable over time and distinguishable from other anxiety disorders.

Supplementary insurance coverage for complementary health services (Yes) 202 55.0 Has a family physician (Yes) 308 83.5 Comorbid anxiety disorder ... professional of GAD in the past 12 months ...

MindMed has dosed the first subject in a Phase III study of MM120 tablets for the treatment of generalised anxiety disorder.

PHOENIXVILLE, PA — Facet Life Sciences has been selected as the U.S. regulatory partner for Cybin Inc., a neuropsychiatry ...

Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...